Human Reproduction, Vol. 14, No. 11, 2709-2715,
November 1999
© 1999 European Society of Human Reproduction and Embryology
Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study
1 Infertility Clinic, The Family Federation of Finland, Kalevankatu 16, FIN-00100 Helsinki and 2 Departments I and II of Obstetrics and Gynaecology, University Central Hospital of Helsinki, Helsinki, Finland
A randomized comparison of two recombinant human follicle-stimulating hormone (recFSH) preparations (Gonal-F® and Puregon®) in ovarian stimulation for in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) was carried out at the Infertility Clinic of the Family Federation of Finland. A total of 348 women (aged 22–43 years) suffering from infertility due to miscellaneous causes was recruited. Of these, 344 underwent stimulation using equal starting doses (150 IU/day: Gonal-F® n = 164, Puregon® n = 158 or 300 IU/day: Gonal-F® n = 8, Puregon® n = 14) after down-regulation with intranasal buserelin from the mid-luteal phase. Similar clinical pregnancy rates were achieved with both preparations; 33.5% per cycle and 37.4% per embryo transfer (24.5% one-embryo and 75.5% two-embryo transfers, n = 147) with Gonal-F® (150 IU/day) and 32.9% per cycle and 36.4% per embryo transfer (30.1% one-embryo and 69.9% two-embryo transfers, n = 145) with Puregon® (150 IU/day). The ongoing cumulative pregnancy rates after frozen–thawed embryo transfer were 35.4% with Gonal-F® and 37.7% with Puregon®. Six cycles were cancelled because of a low response (three in each group). Similar numbers of oocytes were obtained in both groups; 13.0 with 150 IU/day and 6.1 with 300 IU/day Gonal-F®, and 12.4 with 150 IU/day and 7.1 with 300 IU/day Puregon®. The fertilization and cleavage rates and the incidence of moderate or severe ovarian hyperstimulation syndrome (Gonal-F®, 2.0% and Puregon®, 0.7%) were also similar. Gonal-F® and Puregon® were equally and highly effective in stimulation for IVF and ICSI.
Key words: embryo transfer/follicle-stimulating hormone/in-vitro fertilization/intracytoplasmic sperm injection/pregnancy rate
3 To whom correspondence should be addressed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Al-Inany, M. Aboulghar, R. Mansour, and G. Serour Meta-analysis of recombinant versus urinary-derived FSH: an update Hum. Reprod., February 1, 2003; 18(2): 305 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Harlin, A. Aanesen, G. Csemiczky, H. Wramsby, and G. Fried Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation Hum. Reprod., February 1, 2002; 17(2): 304 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, S. Daya, and J. Gunby Meta analysis on rFSH versus uFSH Hum. Reprod., March 1, 2001; 16(3): 593 - 595. [Full Text] [PDF]
|
|